Special Issue "New Therapies and Therapeutic Approaches in Multiple Myeloma"
Deadline for manuscript submissions: closed (31 July 2020).
Interests: multiple myeloma; hematologic cancers; plasma cell biology; bone lesions; bone microenvironment; angiogenesis; smoldering myeloma; monoclonal gammopathy of uncertain significance; hypoxia; monoclonal antibodies; immunomodulatory drugs; proteasome inhibitors.
Special Issues and Collections in MDPI journals
Interests: myeloma therapy; clinical trials; management of complication
Interests: multiple myeloma; target therapies; immunotherapies; elderly patients; frailty
Multiple myeloma (MM) is a hematological malignancy characterized by high tendency to relapse and to develop drug resistance. Despite the recent introduction of new drugs in the therapeutic armamentarium, MM remains an incurable disease. New therapies and new therapeutic approaches need to improve the survival of MM patients. In recent years, the development and the use of monoclonal antibodies against different cell surface antigens overexpressed by MM cells such as CD38, SLAMF7, and BCMA has helped to change the therapeutic paradigm of MM. New possible therapeutic targets for immunotherapy or the use of CAR T cell technology are under clinical investigation, with very promising results. Moreover, selective drug inhibitors such as those anti-BCL-2 and MCL-1 apoptotic proteins or against the nuclear transport exportin (selinexor) are under experimental and clinical investigation.
In the last few years, new therapeutic approaches have been developed. The prolongation of the duration of the treatment and the introduction of the concept of continuous and of maintenance treatment have significantly expanded the results obtained with the first-line treatment, with a consequent improvement of the survival of MM patients. Moreover, combination treatment using both the main class of drugs as proteasome inhibitors and immunomodulatory drugs and monoclonal antibodies seems to extremely prolong the duration of the response of MM patients. Finally, growing evidence indicates the quality of the response to the therapy, evaluated by the minimal residual disease (MRD), is the most important end point related to the duration of remission and the survival. An MRD-driven therapeutic approach could be the optimal strategy for the future in MM patients.
This Special Issue will address the most recent and relevant scientific findings regarding advances in the treatment of MM.
Prof. Dr. Nicola Giuliani
Dr. Francesca Gay
Dr. Sara Bringhen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Multiple myeloma
- New drugs
- Monoclonal antibody
- Minimal residual disease
- Drug combinations